drugset
drugset / Trial / NCT03752398

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

NCT03752398 ↗

Phase 1 Completed 198 enrolled Xencor, Inc. ICON plc · collab
RandomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.

Timeline

Start
2019-05-01
Primary completion
2024-02-15
Completion
2024-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject IZURALIMAB Monoclonal antibody — —
Subject Ipilimumab Monoclonal antibody — —

Indications

cervical carcinoma colorectal carcinoma endometrial carcinoma head and neck squamous cell carcinoma hepatocellular carcinoma melanoma nasopharyngeal carcinoma non-small cell lung carcinoma renal cell carcinoma small cell lung carcinoma triple-negative breast carcinoma undifferentiated pleomorphic sarcoma urothelial carcinoma